Clinical Trial Update: DC Vaccination for Postremission Therapy in AML [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating dendritic cell vaccination as postremission therapy for acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Dendritic Cell Vaccination (dendritic cell vaccine)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED